Naturally Inspired | Scientifically Defined

Specialist in plant derived cell signalling small molecules to address
challenging medical conditions for humans and companion animals

QBiotics doses first Australian patient in Phase I/II clinical trial for head and neck cancer

22 July 2020

  • First Australian patient successfully dosed with tigilanol tiglate at The Kinghorn Cancer Centre, as part of QBiotics' Phase I/II clinical trial in patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
  • The Phase I/II clinical trial is a dose escalation study, designed to determine the optimal dose, safety and tumour response to tigilanol tiglate, a small molecule anticancer agent
  • The multicentre QB46C‐H03 trial is being run at sites in Australia and India
  • Squamous cell carcinoma is the most common type of head and neck cancer with more than 2 million new cases diagnosed each year


PDF documentRead the full announcement